Icon Plc (NASDAQ:ICLR) Receives Average Recommendation of “Hold” from Analysts

by · The Markets Daily

Icon Plc (NASDAQ:ICLR – Get Free Report) has been given a consensus rating of “Hold” by the seventeen analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a sell rating, seven have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $170.40.

A number of research analysts recently commented on ICLR shares. Mizuho upped their price objective on Icon from $180.00 to $190.00 and gave the company an “outperform” rating in a report on Friday, June 26th. Truist Financial restated a “buy” rating and issued a $209.00 target price (up from $207.00) on shares of Icon in a research report on Friday, July 31st. Barclays increased their price target on Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. TD Cowen raised their price objective on Icon from $164.00 to $197.00 and gave the stock a “buy” rating in a research report on Thursday, June 25th. Finally, Citigroup upped their target price on shares of Icon from $165.00 to $180.00 and gave the company a “neutral” rating in a research report on Friday.

View Our Latest Stock Report on ICLR

Icon Trading Down 1.1%

Shares of ICLR opened at $156.70 on Friday. The company has a current ratio of 0.95, a quick ratio of 0.95 and a debt-to-equity ratio of 0.23. Icon has a 12-month low of $66.57 and a 12-month high of $203.91. The firm has a 50-day moving average price of $158.39 and a 200 day moving average price of $134.94. The firm has a market capitalization of $12.00 billion, a P/E ratio of 36.78, a P/E/G ratio of 6.66 and a beta of 1.21.

Icon (NASDAQ:ICLR – Get Free Report) last issued its earnings results on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.55 by $0.01. Icon had a net margin of 3.99% and a return on equity of 8.02%. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $2 billion. During the same period in the previous year, the firm earned $3.26 earnings per share. Icon’s quarterly revenue was up 2.3% compared to the same quarter last year. Sell-side analysts forecast that Icon will post 9.45 EPS for the current year.

Hedge Funds Weigh In On Icon

Several large investors have recently made changes to their positions in the stock. Toth Financial Advisory Corp purchased a new stake in Icon in the fourth quarter valued at approximately $27,000. EFG International AG purchased a new position in shares of Icon during the fourth quarter worth $27,000. Abound Financial LLC purchased a new position in shares of Icon during the fourth quarter worth $54,000. GAMMA Investing LLC raised its holdings in shares of Icon by 21.4% in the 2nd quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock valued at $68,000 after buying an additional 69 shares during the period. Finally, Johnson Financial Group Inc. acquired a new position in Icon during the 3rd quarter worth about $71,000. 95.61% of the stock is currently owned by institutional investors and hedge funds.

About Icon

(Get Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.

Read More